Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Deoxiepinephrine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 4/20 | 0.52 |
| ▸ | SLC6A3 known ✓ | Q01959 | 4/20 | 0.52 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 6/20 | 0.92 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.92 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.92 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.92 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.92 |
| ▸ | THPO | P40225 | 3/20 | 0.92 |
| ▸ | TP53 | P04637 | 2/20 | 0.92 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.92 |
| ▸ | TSHR | P16473 | 2/20 | 0.92 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.92 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.89 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.89 |
| ▸ | LMNA | P02545 | 4/20 | 0.89 |
| ▸ | BLM | P54132 | 3/20 | 0.89 |
| ▸ | HPGD | P15428 | 2/20 | 0.89 |
| ▸ | GFER | P55789 | 2/20 | 0.89 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.89 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Deoxiepinephrine SCHEMBL67772 | 0.96 | MAPT (1.00) | MAPTHIF1AHSD17B10MAPK1ALOX15 | |
| Deoxiepinephrine SCHEMBL29379200 | 0.96 | MAPT (1.00) | MAPTHIF1AHSD17B10MAPK1ALOX15 | |
| Deoxiepinephrine SCHEMBL1320882 | 0.94 | MAPT (1.00) | MAPTHIF1AHSD17B10MAPK1ALOX15 | |
| Deoxiepinephrine SCHEMBL31364234 | 0.94 | MAPT (1.00) | MAPTHIF1AHSD17B10MAPK1ALOX15 | |
| Deoxiepinephrine SCHEMBL7438678 | 0.94 | MAPT (0.96) | MAPTHIF1AHSD17B10MAPK1ALOX15 | |
| Deoxiepinephrine SCHEMBL14918907 | 0.87 | MAPT (0.83) | MAPTHIF1AHSD17B10MAPK1ALOX15 | |
| Deoxiepinephrine SCHEMBL28945910 | 0.86 | MAPT (0.80) | MAPTHIF1AHSD17B10MAPK1ALOX15 | |
| Deoxiepinephrine SCHEMBL31078819 | 0.82 | MAPT (0.73) | MAPTHIF1AHSD17B10MAPK1ALOX15 | |
| SCHEMBL12305680 | 0.81 | MAPT (0.72) | MAPTHIF1AHSD17B10MAPK1ALOX15 | |
| SCHEMBL14472993 | 0.81 | MAPT (0.72) | MAPTHIF1AHSD17B10MAPK1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116905231-A | Polylactic acid composite membrane and preparation method and application thereof | 国能神东煤炭集团有限责任公司 | 2023-10-20 | — | — | CN | disclosed |
| US-9964552-B2 | Mass spectrometric identification and/or quantitation of catecholamines using aminopyrazoles | DH TECHNOLOGIES DEVELOPMENT PTE. LTD. (SG) | 2018-05-08 | — | — | US | disclosed |
| US-20160305969-A1 | MASS SPECTROMETRIC IDENTIFICATION AND/OR QUANTITATION OF CATECHOLAMINES USING AMINOPYRAZOLES | DH TECHNOLOGIES DEVELOPMENT PTE. LTD. (SG) | 2016-10-20 | — | — | US | disclosed |
| US-20140024677-A1 | METHODS FOR INDUCING MITOCHONDRIAL BIOGENESIS | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2014-01-23 | — | — | US | disclosed |
| US-20050271739-A1 | Methods and compositions for accelerating alcohol metabolism | ENZYMEDIX | 2005-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160305969-A1 | MASS SPECTROMETRIC IDENTIFICATION AND/OR QUANTITATION OF CATECHOLAMINES USING AMINOPYRAZOLES | AADAT, AASDHPPT, AANAT | SLC6A2 44/4885SLC6A3 83/4885CHRM1 2102/4885 |
| US-20050271739-A1 | Methods and compositions for accelerating alcohol metabolism | ADH1A, ADH1C, ADH5 | SLC6A2 964/4885SLC6A3 1321/4885CHRM1 2212/4885 |
| US-20140024677-A1 | METHODS FOR INDUCING MITOCHONDRIAL BIOGENESIS | TFAM, TXNRD2, CPT1B | SLC6A2 270/4885SLC6A3 563/4885CHRM1 3806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.